OPM announces the initiation of Phase I of its RIPK2 inhibitor ODS-101, a new therapeutic agent for IBD
- First-in-Man study of ODS-101 in healthy volunteers
Dijon (France), February 9, 2023, at 05:45pm CET– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a clinical stage biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the clinical entry of its drug candidate ODS-101 with the first subject dosing in Phase 1 clinical trial in healthy volunteers.
Philippe Genne, Chairman and CEO of OPM, commented:
“This is a very important milestone for Oncodesign Precision Medicine. After the entry into the clinic of our first drug candidate against Parkinson’s disease in partnership with Servier last September, it is now time for ODS-101 to start its clinical development. This molecule is based on our Nanocyclix® technology and our strategy is to finance the development ourselves until proof of concept in Phase 2a in 2024. Before that, we will determine the most appropriate clinical indication for the continuation of this phase I and finally, we will seek a pharmaceutical licensing partner. We have already demonstrated that we have the capacity to sign this type of international pharmaceutical partnership, and numerous contacts have already been established since the selection of ODS-101. IBD affects over 200,000 people in France and 40% of patients worldwide are non-responders to existing treatments. We will do our best to bring an effective therapeutic alternative to patients suffering from these diseases.”
About the Nanocyclix® technology
The Nanocyclix® technology is based on small macrocyclic molecules designed to inhibit the human kinome (the family of kinases that has more than 500 members), which plays a role in more than 400 diseases. These molecules represent an extraordinary opportunity thanks to their physicochemical properties (low molecular weight, cell membrane crossing, selectivity) to target with high potency and selectivity little explored or notoriously difficult kinases and to obtain drug candidates that meet the specifications compatible with our ambition to deliver therapeutic agents in precision medicine.
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), the result of the transfer of Oncodesign’s Biotech and AI activities, is a biopharmaceutical company specializing in precision medicine to treat resistant and metastatic cancers.
OPM’s innovative technologies are (i) OncoSNIPER for the selection of therapeutic targets using artificial intelligence; (ii) Nanocyclix® for the design and selection of macrocyclic small molecule kinase inhibitors and (iii) Theranostics for the design and selection of radiolabeled biological molecules for systemic radiotherapy.
From these technologies, OPM has built a portfolio of therapeutic products. A first drug candidate based on the Nanocyclix® technology entered the clinical phase in 2022, in partnership with SERVIER (which exercised its option for an exclusive worldwide license on the program) to treat Parkinson’s disease. ODS 101 is OPM’s second candidate to enter the clinic, in the treatment of chronic immuno-inflammatory diseases. Finally, OPM is also collaborating with Servier to discover new therapeutic targets for the treatment of pancreatic adenocarcinoma based on its OncoSNIPER technology. In addition, OPM is seeking a partner for Florepizol, a radiotracer specific for the mutated EGFR target, which has successfully completed Phase 1. Two projects are in early partnership phase with TIUMBIO (pulmonary fibrosis) and SEngine in oncology. Finally, OPM has a significant portfolio of early-stage projects with Nanocyclix® and Theranostics in oncology. With this portfolio of molecules and diversified therapeutic targets, OPM’s mission is to discover effective therapies to treat resistant and advanced cancers. Based in Dijon, at the heart of the university and hospital cluster, OPM has 25 employees.
More information: oncodesign.com